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Abstract
Aims: Second-generation everolimus-eluting stents (EES) are safer and more efficient than first-generation 
paclitaxel-eluting stents (PES). Third-generation biolimus-eluting stents (BES) have been found to be non-
inferior to PES. To date, there is no available comparative study between EES and BES. We aimed to inves-
tigate the safety and efficacy of BES with biodegradable polymer compared to EES with durable polymer at 
a follow-up of two years in an unselected population of consecutively enrolled patients.
Methods and results: A group of 814 consecutive patients undergoing percutaneous coronary intervention 
(PCI) was enrolled between 2007 and 2010, of which 527 were treated with EES and 287 with BES implanta-
tion. Clinical outcome was compared in 200 pairs using propensity score matching. The primary endpoint 
was a composite of death, myocardial infarction (MI) and target vessel revascularisation (TVR) at two-year 
follow-up. Median follow-up was 22 months. The primary outcome occurred in 11.5% of EES and 10.5% of 
BES patients (HR 1.11, 95% CI: 0.61-2.00, p=0.74). At two years, there was no significant difference with 
regard to death (HR 0.49, 95% CI: 0.18-1.34, p=0.17), cardiac death (HR 0.14, 95% CI: 0.02-1.14, p=0.66) 
or MI (HR 6.10, 95% CI: 0.73-50.9, p=0.10). Stent thrombosis (ST) incidence was evenly distributed between 
EES (n=2) and BES (n=2) (p-value=1.0).
Conclusions: This first clinical study failed to demonstrate any significant difference regarding safety or 
efficacy between these two types and generations of drug-eluting stents (DES).
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Abbreviations
BES biolimus-eluting stent
DES drug-eluting stent
EES everolimus-eluting stent
MACE major adverse cardiac events 
MI myocardial infarction
PCI percutaneous coronary intervention
TLR target lesion revascularisation
TVR target vessel revascularisation
Introduction
Drug-eluting stents (DES) lower neointimal hyperplasia and subse-
quent revascularisation in comparison to bare metal stents (BMS). 
However, first-generation DES are associated with a low but sig-
nificant risk of late occurring clinical events such as stent thrombo-
sis or restenosis. These delayed complications are linked to certain 
DES components responsible for chronic inflammatory reactions. 
Therefore, it is considered that changes in key components of first-
generation DES might diminish local inflammatory reactions and 
thus decrease the risk of late events. 
Everolimus-eluting stents (EES) – a second-generation DES – 
are characterised by thinner stent struts and a lower amount of drug 
released through a durable polymer when compared to paclitaxel-
eluting stents (PES). Two large randomised studies (SPIRIT IV and 
COMPARE) have proved EES superiority to PES, and one propen-
sity score matched registry (LESSON-1) has shown a trend towards 
a lower risk of the patient-oriented safety and efficacy endpoint of 
death, MI and TVR as compared to sirolimus-eluting stents (SES) 
during follow-up to three years1-3.These three trials showed a sig-
nificant reduction in definite and probable stent thrombosis during 
long-term follow-up according to the definitions of the Academic 
Research Consortium (ARC)1,4. Other recently published trials, 
such as ISAR-TEST-4 or EXCELLENT, have proved the non-infe-
riority of EES in terms of safety and efficacy when compared with 
SES at three years and nine months, respectively5,6. EES is cur-
rently the most used DES in the USA and in Europe7.
Similarily, biolimus-eluting stents (BES) – a third-generation 
DES – are characterised by a bioabsorbable abluminal polymer 
coating. It is reported that the polylactic polymer is completely con-
verted to lactic acid by six months and, via the Krebs cycle, to car-
bon dioxide and water by six to nine months. BES induce less 
neointimal proliferation than first-generation PES and were non-
inferior for clinical endpoints at nine months in the randomised 
controlled NOBORI trial8. Moreover, in the four-year follow-up 
LEADERS trial, BES were demonstrated to be non-inferior to first-
generation SES and associated with a reduced risk of cardiac events 
associated with very late ST when compared to SES9-12.
To date, no study has directly assessed the safety and efficacy of 
EES versus BES in real life practice. We performed a propensity-
matched analysis to compare the outcomes of consecutively enrolled 
patients who were treated with implantation of EES and BES over 
two years, trying to demonstrate that no difference in mortality, myo-
cardial infarction or TVR existed between these types of stent.
Methods
STUDY POPULATION AND DATA COLLECTION
A total of 527 consecutive patients were treated with EES (XIENCE V; 
Abbott Vascular, Santa Clara, CA, USA, or Promus®; Boston Scientific, 
Natick, MA, USA) between January 2007 and November 2010, 
whereas 287 consecutive patients underwent treatment with BES 
(Nobori®; Terumo Corporation, Tokyo, Japan, or BiomatrixTM; 
 Biosensors International, Singapore) between March 2008 and 
November 2010 at our institution in one single cathlab. All patients 
having received at least one other stent (crossover with study or non-
study stent), patients included in the COMPARE-2 (NCT01233453) 
trial and those with a clinical follow-up of less than 12 months were 
excluded in order to decrease events non-attributable to the studied 
devices. Stent selection in the individual patient was left entirely to 
the operator’s discretion and therefore depended solely upon his rou-
tine. No indications favouring the implantation of EES rather than 
BES or vice versa were present. A prospective clinical follow-up was 
completed in the first 300 patients treated with EES and in the first 
200 patients treated with BES (Figure 1). The study complied with 
the Declaration of Helsinki and was approved by the local ethics 
committee at Fribourg University & Hospital, Switzerland (003-REP-
CER-FR). Written and informed consent for prospective follow-up 
was obtained from every patient.
Patients were clinically followed for at least two years. Information 
regarding clinical status was collected at clinic visits or by telephone 
interview. No blinding was present during the collection of outcome 
data. When the patient was not accessible, data were retrieved from 
the referring physician or hospital electronic database. The institu-
tional angiographic and imaging core laboratories at Fribourg 
University reviewed the cases. Events were adjudicated by the local 
events adjudication committee. Event adjudication was blinded for 
stent type. Every event was reviewed in detail using the medical 
record; if uncertainties were present, the case was reviewed with the 
responsible physician at the time the event occurred.
Patients who received EES and BES
between 2007 and 2010
EES n=527    BES n=287
– Patients participating in other clinical trials
– Crossover with non-/study stent
EES n=41 BES n=12
EXCLUDED
INCLUDED
STUDY POPULATION
EES n=486 BES n=275
AFTER PROPENSITY
SCORE MATCHING
EES n=200       BES n=200
FOLLOW-UP CONDUCTED IN THE FIRST
EES n=300 BES n=200
Figure 1. Flowchart illustrating patient exclusion and inclusion. 
BES: biolimus-eluting stent; EES: everolimus-eluting stent
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Procedures
The treatment guidelines, including periprocedural and post-
procedural medication regimens, were carried out according to 
current practice guidelines and did not change between the 
inclusion of the first and last patients of both EES and BES 
cohorts. All patients received a 600 mg clopidogrel loading dose 
during the procedure and were prescribed lifelong aspirin once 
daily as well as clopidogrel for 12 months. The use of glycopro-
tein IIb/IIIa antagonists was at the discretion of the operator. 
Creatinine kinase (CK), CK-MB, and troponin I were routinely 
assessed at baseline and four to six hours post-PCI as was a 
12-lead electrocardiogram (ECG). Biomarkers were sampled 
every six to eight hours in patients with signs of ischaemia until 
identification of peak levels. IVUS-guided stenting was not rou-
tinely performed at our institution.
Definitions
The primary endpoint was the composite of death, MI, and target 
vessel revascularisation (TVR) up to a maximum two-year follow-
up. Hypercholesterolaemia was defined according to the Adult 
Treatment Panel III13. Heart failure was classified as being either 
present or absent according to the clinical definition of the New 
York Heart Association14. Acute coronary syndromes (ACS) were 
defined according to the consensus paper from the ESC–ACC–
AHA–WHF Joint Force15. Cardiogenic shock was defined as sus-
tained hypotension (systolic blood pressure [BP] <90 mmHg 
lasting >30 minutes) accompanied by signs of tissue hypoperfusion 
in the setting of clinically adequate or elevated left ventricular fill-
ing pressures16. The definition of cardiac death included any death 
due to immediate cardiac cause, procedure-related deaths, and 
death of unknown cause. The diagnosis of Q-wave MI required 
ischaemic signs or symptoms and new pathological Q-waves in ≥2 
contiguous ECG leads. In the absence of Q-waves, the diagnosis of 
MI was based on an elevation of CK to higher than twice the upper 
reference limit and elevation of CK-MB or troponin to higher than 
the upper reference limit. Periprocedural MI was defined as tro-
ponin or CK-MB elevation of at least three times URL during inter-
vention or in the subsequent 48 hours after PCI, and was included 
in the total number of MI.
TVR was defined as repeat revascularisation of any segment 
within the entire major coronary vessel proximal and distal to a tar-
get lesion. Target lesion revascularisation (TLR) was defined as 
revascularisation for a stenosis within the stent or the 5 mm borders 
adjacent to the stent. ST was defined according to Academic 
Research Consortium (ARC) definitions4. MACE were equally 
defined according to the ARC definitions and were therefore the 
composite of cardiac death, non-fatal MI and TVR. Of note, staged 
procedures performed >3 months after the index procedure were 
considered as revascularisation.
Statistical analysis
This was a propensity score (PS) matched analysis. Analyses were 
performed using SPSS software 18.0 (SPSS Inc., Chicago, IL, USA). 
A power analysis revealed that, assuming a small effect size and 
an alpha of 0.05, a two-sample comparison of proportions with 
200 patients in each group would yield a power of 34%. We com-
pared baseline characteristics between patients treated with EES 
and BES using a chi-square test for categorical variables and an 
unpaired t-test for continuous variables with a normal distribution 
and non-parametric tests such as the Wilcoxon rank sum test for 
continuous variables with a non-Gaussian distribution. We then 
used PS matching to account for differences in baseline character-
istics. A PS for receiving EES was estimated using a probit model 
including age, gender, and pre-treatment variables associated with 
stent selection in the multivariable model at p<0.10 as independent 
variables (hypercholesterolaemia, heart failure and a history of pre-
vious PCI). The matching balance of covariates was then assessed 
using standard chi-square algorithms. The multivariable model was 
computed using the forward stepwise selection. In the matching 
procedure we used the caliper matching approach that randomly 
selected a patient treated with EES with one treated with BES from 
the pool of patients within a caliper of ±0.05 on the propensity 
score. We used Cox proportional hazard models that accounted for 
the 1:1 matching, including all variables that significantly differed 
between the two groups in order to calculate hazard ratios (HR) 
comparing the two stents, and in that way tried to adjust for con-
founders of the relation between stent choice and clinical outcomes. 
All p-values and 95% confidence intervals (CIs) are two-sided.
Results
BASELINE PATIENT CHARACTERISTICS
Baseline patient characteristics before and after PS are summarised 
in Table 1. Of 200 patients who received a BES, the Biomatrix stent 
was implanted in 148 (74%) and the Nobori stent was implanted in 
52 (26%) patients. Before PS matching, EES patients were older 
(67.3±11.2 vs. 64.9±10.7 years, p=0.02), presented less family his-
tory of coronary artery disease (CAD) (15.3% vs. 24.0%, p=0.02), 
were more prone to heart failure (11.7% vs. 3.0%, p=0.001) and 
more frequently had a history of previous PCI (32.7% vs. 20.5%, 
p=0.03) than BES. No statistically significant differences remained 
after PS matching.
BASELINE LESION AND PROCEDURAL CHARACTERISTICS
Baseline lesion and procedural characteristics are summarised in 
Table 2. The two groups were well balanced according to the num-
ber of lesions and vessels treated, rate of multivessel treatment, tar-
get vessel distribution, number of stents implanted and average 
stent diameter. However, a small but significant difference was seen 
in total stent length (EES: 35.7±24.6 mm vs. BES: 31.8±22.2 mm, 
p=0.04) and a trend towards higher implantation pressure in the 
EES group (EES: 15.3±3.2 atm vs. BES: 14.7±3.3 atm, p=0.06).
CLINICAL FOLLOW-UP
The median follow-up duration was 21.3 months [IQR 13.8-27.1] 
before and 22.0 months [IQR 14.0-30.9] after PS matching. Table 3 
presents clinical outcomes up to two years. The primary outcome 
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Table 1. Baseline patient characteristics before and after propensity score matching.
Before propensity score matching After propensity score matching
Everolimus-
eluting stent 
(n=300)
Biolimus 
eluting stent 
(n=200)
p-value
Everolimus-
eluting stent 
(n=200)
Biolimus 
eluting stent 
(n=200)
p-value
Age, years±SD 67.3±11.2 64.9±10.7 0.02 65.9±11.2 64.9±10.7 0.31
Male sex, n (%) 227 (75.7) 146 (73.0) 0.5 151 (75.5) 146 (73.0) 0.49
Body mass index, kg/m2±SD 27.6±4.3 27.2±4-0 0.47 27.4±4.1 27.2±4.0 0.77
Diabetes 0.35 0.21
Insulin dependent, n (%) 20 (6.7) 9 (4.5) 16 (8.0) 9 (4.5)
Non-insulin dependent, n (%) 37 (12.3) 21 (10.5) 24 (12.0) 21 (12.5)
Current smoker, n (%) 101 (33.7) 75 (37.5) 0.48 69 (34.5) 75 (37.5) 0.36
Dyslipidaemia, n (%) 163 (54.3) 123 (61.5) 0.11 121 (60.5) 123 (61.5) 0.84
Hypertension, n (%) 171 (57.0) 116 (58.0) 0.83 109 (54.5) 116 (58.0) 0.48
Family history, n (%) 46 (15.3) 48 (24.0) 0.02 41 (20.5) 48 (24.0) 0.4
Renal failure, n (%) 17 (5.7) 11 (5.5) 0.94 6 (3.0) 11 (5.5) 0.22
EF less than 50%, n (%) 32 (10.7) 13 (6.5) 0.27 9 (4.5) 13 (6.5) 0.41
Previous MI, n (%) 61 (20.3) 31 (15.5) 0.17 24 (12.0) 31 (15.5) 0.31
Previous PCI, n (%) 98 (32.7) 41 (20.5) 0.03 36 (18.0) 41 (20.5) 0.53
Previous CABG, n (%) 28 (9.3) 19 (9.5) 0.95 17 (8.5) 19 (9.5) 0.73
Chronic angina/silent ischaemia, n (%) 114 (38.0) 80 (40) 0.02 71 (35.5) 80 (40) 0.49
ACS, n (%) 152 (50.7) 108 (54.0) 110 (55) 108 (54.0
NSTEMI, n (%) 59 (19.7) 47 (23.5) 0.07 47 (23.5) 47 (23.5) 0.91
STEMI, n (%) 59 (19.7) 53 (26.5) 0.07 42 (21.0) 53 (26.5) 0.20
Cardiogenic shock, n (%) 4 (1.3) 1 (0.5) 0.36 3 (1.5) 1 (0.5) 0.32
ACS: acute coronary syndrome; CABG: coronary artery bypass graft, MI: myocardial infarction; NSTEMI: non-ST-elevation myocardial infarction; 
PCI: percutaneous coronary intervention; STEMI: ST-elevation myocardial infarction 
Table 2. Baseline lesion and procedural characteristics before and after propensity score matching.
Before propensity  score matching After propensity score matching
Everolimus-
eluting stent
(n=300)
Biolimus-
eluting stent
(n=200)
p-value
Everolimus-
eluting stent
(n=200)
Biolimus-
eluting stent
(n=200)
p-value
Multivessel treatment, n (%) 45 (15.0) 17 (8.5) 0.03 21 (10.5) 17 (8.5) 0.58
Number of vessels treated per patient, n (SD) 1.16±0.4 1.1±0.3 0.03 1.1±0.3 1.1±0.3 0.49
Number of lesions treated per patient, n (SD) 1.7±1.0 1.8±1.1 0.87 1.7±1.0 1.8±1.1 0.72
1 lesion 170 (56.7) 113 (56.5) 115 (57.5) 113 (56.5)
2 lesions 76 (25.3) 49 (24.5) 52 (26.0) 49 (24.5)
3 lesions 33 (11.0) 21 (10.5) 18 (9.0) 21 (10.5)
≥ 4 lesions 21 (7.0) 17 (8.5) 15 (7.5) 17 (8.5)
Target vessel – number of patients
Left main, n (%) 4 (1.3) 2 (1.0) 0.74 2 (1.0) 2 (1.0) 1
Left anterior descending artery, n (%) 138 (46.0) 87 (43.5) 0.58 86 (43) 87 (43.5) 0.92
Left circumflex, n (%) 89 (29.7) 52 (26.0) 0.37 53 (26.5) 52 (26.0) 0.91
Right coronary artery, n (%) 110 (36.7) 72 (36.0) 0.88 75 (37.5) 72 (36.0) 0.76
Arterial bypass grafting, n (%) 1 (0.5) 0 (0) 0.41 1 (0.5) 0 (0) 0.32
Saphenous vein graft, n (%) 7 (2.3) 4 (2.0) 0.80 4 (2.0) 4 (2.0) 1
Number of stents per patient, n (SD) 2.2±1.4 2.1±1.4 0.11 2.2±1.4 2.1±1.4 0.16
Average stent diameter, n (SD) 3.1±1.6 3.1±0.7 0.34 3.0±0.5 3.1±0.7 0.81
Total stent length per patient, mm (SD) 35.9±23.9 31.8±22.2 0.02 35.7±24.6 31.8±22.2 0.04
Maximal inflation pressure, atm (SD) 15.6±3.6 14.7±3.3 0.05 15.3±3.2 14.7±3.3 0.06
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Table 3A. Clinical outcomes before propensity score matching.
Everolimus-eluting stent 
(n=300)
Biolimus-eluting stent
(n=200)
Hazard ratio
(95% CI)
p-value
30 days, n (%)
Death 2 (0.7) 3 (1.5) 0.35 (0.04-3.41) 0.37
Cardiac death 1 (0.3) 3 (1.5) 0.22 (0.02-2.14) 0.19
MI 3 (1.0) 0 (0.0) 0.43
TLR 2 (0.7) 3 (1.5) 0.35 (0.04-3.39) 0.37
TVR 4 (1.3) 4 (2.0) 0.53 (0.10-2.91) 0.47
Primary outcome 9 (3.0) 6 (3.0) 1.04 (0.34-3.23) 0.95
Any MACE 8 (2.7) 6 (3.0) 0.86 (0.26-2.81) 0.80
1 year, n (%)
Death 8 (2.7) 10 (5.0) 0.31 (0.08-1.11) 0.07
Cardiac death 5 (1.7) 6 (3.0) 0.17 (0.02-1.42) 0.10
MI 6 (2.0) 1 (0.5) 4.32 (0.48-39) 0.19
TLR 6 (2.0) 4 (2.0) 0.78 (0.17-3.49) 0.75
TVR 15 (5.0) 10 (5.0) 0.92 (0.37-2.27) 0.86
Primary outcome 27 (9.0) 18 (9.0) 0.85 (0.43-1.68) 0.63
Any MACE 24 (8.0) 14 (7.0) 0.95 (0.44-2.01) 0.89
Up to 2 years, n (%)
Death 14 (4.7) 11 (5.5) 0.49 (0.18-1.34) 0.17
Cardiac death 7 (2.3) 7 (3.5) 0.14 (0.02-1.14) 0.07
MI 9 (3.0) 1 (0.5) 6.10 (0.73-50.9) 0.10
TLR 9 (3.0) 5 (2.5) 0.79 (0.21-2.95) 0.73
TVR 22 (7.3) 12 (6.0) 1.13 (0.52-2.45) 0.76
Primary outcome 40 (13.3) 21 (10.5) 1.04 (0.58-1.89) 0.89
Any MACE 33 (11.0) 17 (8.5) 1.02 (0.52-1.98) 0.96
MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularisation; TVR: target vessel revascularisation
Table 3B. Clinical outcomes after propensity score matching.
Everolimus- eluting stent
(n=200)
Biolimus-eluting stent
(n=200)
Hazard ratio
(95% CI)
p-value
30 days, n (%)
Death 1 (0.5) 3 (1.5) 0.37 (0.04-3.41) 0.35
Cardiac death 0 (0.0) 3 (1.5) 0.02 (0.00-164) 0.38
MI 3 (1.5) 0 (0.0) 0.14
TLR 1 (0.5) 3 (1.5) 0.35 (0.04-3.39) 0.37
TVR 2 (1.0) 4 (2.0) 0.53 (0.10-2.91) 0.47
Primary outcome 6 (3.0) 6 (3.0) 1.04 (0.34-3.23) 0.95
Any MACE 5 (2.5) 6 (3.0) 0.86 (0.26-2.81) 0.80
1 year, n (%)
Death 3 (1.5) 10 (5.0) 0.31 (0.08-1.11) 0.07
Cardiac death 1 (0.5) 6 (3.0) 0.17 (0.02-1.42) 0.10
MI 4 (2.0) 1 (0.5) 4.32 (0.47-39.4) 0.19
TLR 3 (1.5) 4 (2.0) 0.78 (0.17-3.49) 0.75
TVR 9 (4.5) 10 (5.0) 0.92 (0.37-2.27) 0.86
Primary outcome 15 (7.5) 18 (9.0) 0.85 (0.43-1.68) 0.63
Any MACE 13 (6.5) 14 (7.0) 0.95 (0.44-2.01) 0.89
Up to 2 years, n (%)
Death 6 (3.0) 11 (5.5) 0.49 (0.18-1.34) 0.17
Cardiac death 1 (0.5) 7 (3.5) 0.14 (0.02-1.14) 0.66
MI 6 (3.0) 1 (0.5) 6.10 (0.73-50.9) 0.10
TLR 4 (2.0) 5 (2.5) 0.79 (0.21-2.95) 0.73
TVR 14 (7.0) 12 (6.0) 1.13 (0.52-2.45) 0.76
Primary outcome 23 (11.5) 21 (10.5) 1.11 (0.61-2.00) 0.74
Any MACE 18 (9.0) 17 (8.5) 1.10 (0.56-2.13) 0.79
MACE: major adverse cardiac events; MI: myocardial infarction; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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occurred in 11.5% of EES-treated and 10.5% of BES-treated 
patients up to two years (HR 1.11; 95% CI: 0.61-2.00; p=0.74). 
Figure 2 and Figure 3 depict Kaplan-Meier survival-free curves 
for death, MACE and the primary outcome up to two-year follow-
up before and after propensity score matching. Rates of all-cause 
and cardiac mortality were similar, whereas myocardial infarction 
(3.0% vs. 0.5%; HR 6.10, 95% CI: 0.73-50.9; p=0.10) was slightly 
less frequent with BES. The incidence rate for the primary end-
point was 5.2% per year in the EES group and 6.6% per year in the 
BES group. Regarding MACE, the incidence rates were 4.1% and 
5.4% per year in the EES and BES groups, respectively. Angio-
graphically documented and therefore definite ST occurred in two 
patients (1%) within the EES group (one subacute and one late 
ST) and in one BES patient (subacute ST). The stent thromboses 
accounted for two of the three cardiac deaths in the first month in 
the BES group. The other patient died due to cardiac tamponade. 
Rates of overall probable and definite ST were similar with EES 
and BES (definite and probable ST - EES 2 (1.0%) versus BES 2 
(1.0%); p=1.0). 
Discussion 
This first EES versus BES comparative study has the following 
principal finding: BES with biodegradable polymer is similar to 
EES with durable polymer in the composite primary endpoint of 
death, myocardial infarction, and TVR up to two years in an unse-
lected patient population. No differences regarding efficacy – such 
as TLR – or safety outcomes – such as ST – could be seen between 
the new-generation biolimus-releasing stent from a biodegradable 
polymer and an everolimus-releasing stent from a durable polymer 
as used in routine clinical practice.
Considering that durable polymers are incriminated in the 
pathogenesis of late fatalities (restenosis or thrombosis), BES with 
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Figure 2. Kaplan-Meier curves for survival (A), survival free of TLR (B), MACE (C) and the primary endpoint (D) according to stent type 
implanted after propensity score matching. BES: biolimus-eluting stent; EES: everolimus-eluting stent; MACE: major adverse cardiac events
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bioresorbable polymer offers a theoretical advantage over EES. 
Our study, however, failed to demonstrate this benefit on a mean 
22 months follow-up. Several putative factors could interplay and 
be responsible for this lack of drastically improved effectiveness. 
Firstly, this is in line with previous findings from the LEADERS 
study. If LEADERS could demonstrate a marginal advantage of 
BES over the first-generation SES during extended follow-up, the 
advantage remained statistically insignificant at two-year follow-
up. This has recently been confirmed in a pooled individual analy-
sis of patient data from ISAR-TEST-3, -4, and LEADERS17. 
Secondly, EES is associated with lower drug content and a more 
biocompatible polymer than first-generation stents18. As such, the 
number of very late events has been significantly decreased in 
comparison with other DES19. This is nicely demonstrated in 
a pooled data analysis of the SPIRIT and COMPARE trials in 6,789 
patients with a two-year follow-up, where significant reductions of 
acute MI (2.9% in EES versus 5.5% in PES), TLR (4.1% vs. 
6.6%) and ST (definite/probable: 0.7% versus 2.3%) were demon-
strated20. The same holds true in the EES versus SES LESSON-1 
trial at two years. Moreover, Baber and colleagues demonstrated 
the low incidence of ST in a meta-analysis of 13 randomised 
 controlled trials21. Finally, BES is no panacea since the lactic 
 acidification of the media from the polymer could impact on 
 vascular healing in the stent vicinity and promote an inflammatory 
reaction22.
It will therefore be difficult to see any significant differences 
between BES and EES. Large-scale randomised controlled trials, 
such as the COMPARE-2 (n=2,400 patients) or BASKET-PROVE 
2 (n=2,400 patients) should present results that could further help 
to demonstrate the relative safety of BES compared to EES and 
should have enough statistical power to evaluate individual end-
points and MACE predictors. 
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Figure 3. Kaplan-Meier curves for survival (A), survival free of TLR (B), MACE (C) and the primary endpoint (D) according to stent type 
implanted before propensity score matching. BES: biolimus-eluting stent; EES: everolimus-eluting stent, MACE: major adverse cardiac events
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Limitations
There are some threats to the internal validity of our study. First and 
foremost, we have to note the lack of randomisation. A non-ran-
domised population suffers from a selection bias that even a pro-
pensity score cannot account for, as some relevant subject-related 
variables have not been distributed by chance alone. Furthermore, 
we have to note the experimenter bias which exists in the present 
study in the form of stent selection by the operator who was not 
blinded, and the equally non-blinded collection of outcome data. 
The threat to external validity is the lack of power, resulting from 
the small sample size, and therefore the lack of statistical signifi-
cance with regard to type II errors. Furthermore, external validity is 
compromised by selection, and generalisations must be drawn with 
caution from a population that is subject to such selection. 
Conclusion
This first clinical study failed to demonstrate any significant differ-
ences regarding safety or efficacy between these two types and gen-
erations of drug-eluting stents. This is reassuring but might also 
reflect too small a sample size. Therefore, large randomised trials 
are needed to corroborate the findings of the present study.
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